3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Ovarian Neoplasms
4
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Interventions
Temozolomide
15
Radiotherapy
10
Radiation
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
5
Specimen Handling
5
Ipilimumab
3
atezolizumab
2
Photons
2
Nivolumab
2
Biopsy
2
veliparib
1
selinexor
1
sargramostim
1
plerixafor
1
peposertib
1
pazopanib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
montanide ISA 51
1
liposomal doxorubicin
1
gosha-jinki-gan
1
fluorodopa F 18
1
ferric pyrophosphate
1
efineptakin alfa
1
cemiplimab
1
cabozantinib
1
balstilimab
1
abexinostat
1
X-Rays
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gliosarcoma
×
ipatasertib
×
1 year
×
Clear all
No trials found.